Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Corporate Authors:
      SpIDnet group1
    • المصدر:
      Publisher: National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC) Country of Publication: United States NLM ID: 9508155 Publication Model: Print Cited Medium: Internet ISSN: 1080-6059 (Electronic) Linking ISSN: 10806040 NLM ISO Abbreviation: Emerg Infect Dis Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Atlanta, GA : National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), [1995-
    • الموضوع:
      Pneumococcal Infections*/epidemiology ; Pneumococcal Infections*/prevention & control ; Streptococcus pneumoniae*; Adolescent ; Adult ; Child ; Child, Preschool ; Europe/epidemiology ; Humans ; Infant ; Middle Aged ; Pneumococcal Vaccines ; Serogroup ; Vaccines, Conjugate ; Young Adult
    • نبذة مختصرة :
      We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution. In 2018, serotypes in the 15-valent and 20-valent PCVs represented one third of cases in children <5 years of age and two thirds of cases in persons >65 years of age. Non-PCV13 serotype increases reduced the overall effect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.
    • References:
      Clin Microbiol Infect. 2020 Jun;26(6):753-759. (PMID: 31756452)
      Vaccine. 2018 Jan 25;36(4):572-577. (PMID: 29258705)
      Int J Infect Dis. 2019 Sep;86:122-130. (PMID: 31283992)
      Lancet Infect Dis. 2019 Dec;19(12):1283-1284. (PMID: 31782390)
      Vaccine. 2015 Jan 3;33(2):359-66. (PMID: 25448105)
      PLoS One. 2019 Aug 1;14(8):e0220453. (PMID: 31369597)
      PLoS Med. 2013;10(9):e1001517. (PMID: 24086113)
      Hum Vaccin Immunother. 2019;15(3):530-539. (PMID: 30648919)
      Epidemiol Mikrobiol Imunol. 2019 Spring;68(2):75-81. (PMID: 31398980)
      Lancet Respir Med. 2017 Aug;5(8):648-656. (PMID: 28359798)
      Expert Rev Vaccines. 2018 Jun;17(6):479-493. (PMID: 29241390)
      Expert Rev Vaccines. 2019 Nov;18(11):1145-1155. (PMID: 31682762)
      Vaccine. 2017 Aug 16;35(35 Pt B):4587-4593. (PMID: 28716556)
      Thorax. 2019 May;74(5):473-482. (PMID: 30355641)
      Vaccine. 2013 Nov 19;31(48):5634-42. (PMID: 23856332)
      Vaccine. 2019 Jul 26;37(32):4491-4498. (PMID: 31272872)
      Vaccine. 2019 Sep 30;37(42):6201-6207. (PMID: 31495592)
      PLoS One. 2017 Jan 6;12(1):e0169368. (PMID: 28061505)
      Clin Infect Dis. 2020 Nov 5;71(8):e235-e243. (PMID: 31955196)
      PLoS One. 2015 Jun 30;10(6):e0131117. (PMID: 26125583)
      Lancet Infect Dis. 2018 Apr;18(4):441-451. (PMID: 29395999)
      PLoS One. 2016 Jan 13;11(1):e0146338. (PMID: 26761816)
      Epidemiol Infect. 2017 Aug;145(11):2390-2399. (PMID: 28712384)
      Vaccine. 2018 Jan 8;36(3):421-426. (PMID: 29224962)
      BMC Med Res Methodol. 2008 Nov 27;8:79. (PMID: 19036172)
      Lancet Infect Dis. 2019 Jun;19(6):e213-e220. (PMID: 30709666)
      BMJ. 2011 Feb 10;342:d549. (PMID: 21310794)
      Hum Vaccin Immunother. 2016;12(2):358-74. (PMID: 26905681)
      Genes (Basel). 2019 Oct 25;10(11):. (PMID: 31731573)
      Lancet Infect Dis. 2011 Oct;11(10):760-8. (PMID: 21621466)
      Clin Infect Dis. 2017 Nov 13;65(11):1780-1789. (PMID: 29020171)
      Lancet Glob Health. 2017 Jan;5(1):e51-e59. (PMID: 27955789)
      Lancet. 2011 Dec 3;378(9807):1962-73. (PMID: 21492929)
      PLoS One. 2016 Mar 08;11(3):e0151125. (PMID: 26953887)
      Clin Infect Dis. 2020 Jun 10;70(12):2484-2492. (PMID: 31402387)
    • Contributed Indexing:
      Keywords: 10-valent pneumococcal vaccine; 13-valent pneumococcal vaccine; 15-valent pneumococcal vaccine; 20-valent pneumococcal vaccine; SpIDnet Multicenter Study; Streptococcus pneumoniae; bacteria; invasive pneumococcal disease; pneumococcal infections; respiratory infections; serotype
    • الرقم المعرف:
      0 (Pneumococcal Vaccines)
      0 (Vaccines, Conjugate)
    • الموضوع:
      Date Created: 20211221 Date Completed: 20220106 Latest Revision: 20230915
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC8714201
    • الرقم المعرف:
      10.3201/eid2801.210734
    • الرقم المعرف:
      34932457